Marimastat oral matrix metalloproteinase inhibitor: 300-patient two-year study in the U.S., U.K. and Europe.

British Biotech plc (BBIOY), Oxford, U.K. Product: Marimastat oral matrix metalloproteinase inhibitor Indication: Pancreatic cancer Status: Will start this week a pivotal 300-patient two-year study in...